These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15655007)

  • 21. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya.
    Amin AA; Zurovac D; Kangwana BB; Greenfield J; Otieno DN; Akhwale WS; Snow RW
    Malar J; 2007 May; 6():72. PubMed ID: 17535417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New combination drug to treat malaria.
    Das P
    Lancet Infect Dis; 2005 May; 5(5):267. PubMed ID: 15889476
    [No Abstract]   [Full Text] [Related]  

  • 23. The paradox of home management of malaria with artemisinin combinations.
    Charlwood D
    Trends Parasitol; 2004 Sep; 20(9):405-6. PubMed ID: 15324729
    [No Abstract]   [Full Text] [Related]  

  • 24. Intravenous artesunate recommended for patients with severe malaria: position statement from TropNetEurop.
    Jelinek T
    Euro Surveill; 2005 Nov; 10(11):E051124.5. PubMed ID: 16794288
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of malaria: prevention of resistance by combinations of antimalarial agents].
    Ambroise-Thomas P
    Med Trop (Mars); 2000; 60(3):219-22. PubMed ID: 11258051
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of dihydroartemisinin-piperaquine.
    Myint HY; Ashley EA; Day NP; Nosten F; White NJ
    Trans R Soc Trop Med Hyg; 2007 Sep; 101(9):858-66. PubMed ID: 17659311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Policy brief on improving access to artemisinin-based combination therapies for malaria in the East African community.
    Nabudere H; Upunda GL; Juma M
    Int J Technol Assess Health Care; 2010 Apr; 26(2):255-9. PubMed ID: 20392338
    [No Abstract]   [Full Text] [Related]  

  • 28. Malaria: severe, life threatening.
    Omari A; Garner P
    Clin Evid; 2004 Dec; (12):1150-63. PubMed ID: 15865710
    [No Abstract]   [Full Text] [Related]  

  • 29. [Efficacy of mefloquine, halofantrine, and coarteme in the treatment of tropical malaria].
    Popov AF; Morokov VS; Chirkov VP; Popova NI; Lama N
    Med Parazitol (Mosk); 2002; (1):28-9. PubMed ID: 12224261
    [No Abstract]   [Full Text] [Related]  

  • 30. Adherence to a combination of artemether and lumefantrine (Coartem) in Kajo Keji, southern Sudan.
    Depoortere E; Salvador ET; Stivanello E; Bisoffi Z; Guthmann JP
    Ann Trop Med Parasitol; 2004 Sep; 98(6):635-7. PubMed ID: 15324470
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effect of qinghaosu by rectal administration in the treatment of vivax malaria].
    Li YQ
    Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 1984; 2(4):279. PubMed ID: 6394177
    [No Abstract]   [Full Text] [Related]  

  • 32. Suspected allergy to artemether-lumefantrine treatment of malaria.
    Krippner R; Staples J
    J Travel Med; 2003; 10(5):303-5. PubMed ID: 14531988
    [No Abstract]   [Full Text] [Related]  

  • 33. A contrarian view of malaria therapy policy in Africa.
    Bloland PB
    Am J Trop Med Hyg; 2003 Feb; 68(2):125-6. PubMed ID: 12641398
    [No Abstract]   [Full Text] [Related]  

  • 34. The antimalarial drug artemisinin alkylates heme in infected mice.
    Robert A; Benoit-Vical F; Claparols C; Meunier B
    Proc Natl Acad Sci U S A; 2005 Sep; 102(38):13676-80. PubMed ID: 16155128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimalarial drug resistance in Africa: key lessons for the future.
    Takala-Harrison S; Laufer MK
    Ann N Y Acad Sci; 2015 Apr; 1342():62-7. PubMed ID: 25891142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging drug--resistance and guidelines for treatment of malaria.
    Khan MA; Smego RA; Razi ST; Beg MA
    J Coll Physicians Surg Pak; 2004 May; 14(5):319-24. PubMed ID: 15225468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of large-scale rectal artesunate deployment in the emergency management of malaria.
    Wkly Epidemiol Rec; 2002 Mar; 77(12):93-4. PubMed ID: 11951343
    [No Abstract]   [Full Text] [Related]  

  • 38. In vitro activity of artemisinin alone and in combination with retinol against Plasmodium falciparum.
    Thriemer K; Wernsdorfer G; Rojanawatsirivet C; Kollaritsch H; Sirichainsinthop J; Wernsdorfer WH
    Wien Klin Wochenschr; 2005; 117 Suppl 4():45-8. PubMed ID: 16416385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Healthcare professionals' perspective can guide post-marketing surveillance of artemisinin-based combination therapy in Uganda.
    Ndagije HB; Kiguba R; Manirakiza L; Kirabira E; Sserwanga A; Nabirye L; Mukonzo J; Olsson S; Spinewine A; D'Hoore W; Speybroeck N
    Malar J; 2020 Feb; 19(1):63. PubMed ID: 32041619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deploying triple artemisinin-based combination therapy (TACT) for malaria treatment in Africa: ethical and practical considerations.
    Tindana P; de Haan F; Amaratunga C; Dhorda M; van der Pluijm RW; Dondorp AM; Cheah PY
    Malar J; 2021 Feb; 20(1):119. PubMed ID: 33639946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.